Browse Careers
Browse Investors

Bard Acquires Vacuum-Assisted Biopsy Device

MURRAY HILL, N.J., Jul 24, 2003 (BUSINESS WIRE) -- C. R. Bard, Inc. (NYSE:BCR) today announced that it has acquired assets related to the manufacture and distribution of a new biopsy device from BIP Biomedical Instruments and Products GmbH (BIP), located in Turkenfeld, Germany. Bard Peripheral Vascular, Inc., Bard's subsidiary located in Tempe, Arizona, will market the product. Terms of the transaction were not disclosed.

The new minimally invasive device has a proprietary vacuum-assisted design. It is initially targeted at breast biopsies, for which there are an estimated 2.3 million procedures performed annually around the world. Approximately half of these procedures are performed using less invasive biopsy devices with the balance done surgically. Bard's new biopsy product is a self-contained, portable unit that fits into the physician's hand, providing optimal control, accuracy and flexibility for biopsy procedures. The device is suitable for use with a range of imaging technologies including stereotactic x-ray and ultrasound. In 1995, Bard acquired BIP's Magnum(R) core needle biopsy device, which is the current market leader for spring-loaded core needle biopsies.

William H. Longfield, chairman and chief executive officer, commented, "This acquisition leverages our market leadership position in core needle biopsy, enabling us to enter the larger and faster growing vacuum-assisted segment. It is consistent with our objective to acquire early stage technology to enhance our franchises and improve our sales growth."

The company said that this transaction does not change its guidance for 2003.

This press release contains forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Please refer to our March 31, 2003, Form 10-Q for a statement with regard to forward-looking statements, including disclosure of additional factors that could cause actual results to differ materially from those expressed or implied.

C. R. Bard, Inc., ( headquartered in Murray Hill, N.J., is a leading multinational developer, manufacturer, and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

SOURCE: C. R. Bard, Inc.

C. R. Bard, Inc., Murray Hill
Investor Relations:
Eric J. Shick, 908-277-8413
Media Relations:
Holly P. Glass, 703-754-2848
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.


Primary Media Relations Contact

Scott Lowry
Vice President and Treasurer
C. R. Bard, Inc.
730 Central Avenue
Murray Hill, NJ 07974

Tel: 908-277-8365